Vaccinating the global population against COVID-19 is one of the most immense distribution and logistical challenges humanity has ever faced. Some are hoping that artificial intelligence and blockchain technology can help with the task. By Jeremy Kahn with Fortune Vaccinating the global population against COVID-19
In less than a year, the world has come together to develop effective COVID-19 vaccines and a multilateral platform for allocating them most efficiently around the world. But with the risk of vaccine nationalism still looming large, now is the time to finish the job.
Med Aditus was featured in the Biz Briefs section of Durham Magazine’s December 2020/January 2021 issue. What a great way to start the New Year! For the full feature, please click here.
Government is looking to attract alternative financing for early stage ventures if the new draft law relating to investment promotion and facilitation is passed by the cabinet. By Julius Bizimungu with The New Times Rwanda Government is looking to attract alternative financing for early stage
By Emmanuel Ntirenganya with The New Times Rwanda The World Bank’s Board of Directors on December 16, 2020 approved $150 million (about Rwf145 billion) in International Development Association (IDA) financing for a programme of policy and institutional reforms intended to accelerate human capital development for inclusive
By Jayasree Iyer, Thomas Collin Lefebvre The advent of artificial intelligence as an adaptive and predictive technology offers the possibility for radical optimization of business practices, reshaping market opportunities for pharmaceutical companies and ultimately challenging the status quo on access to medicine worldwide. However, pharmaceutical
CDC Group, Development Partners International, and the European Bank for Reconstruction and Development to combine Egyptian pharmaceuticals manufacturer with Indian generic drugs company to create a new platform for delivering affordable treatments. Platform has received an initial $250 million in capital from its founding investors
In 2017, Kenya became the first country in Africa to receive the generic treatment with an initial 27,000 HIV patients who had developed resistance to efavirenz as first recipients of the drug for free before production was escalated to reach more patients. By Brian Ambani &
